Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital.

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

Aurinia Pharmaceuticals, an autoimmune disease specialist, is trading lower on high volume today. The biotech's shares have been trading at a premium all year long.

Why Aurinia Pharmaceuticals Stock Is Slumping Today

Alpine Immune Sciences

Corcept Therapeutics

Cardiol Therapeutics

KalVista Pharma

Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

The average of price targets set by Wall Street analysts indicates a potential upside of 42.9% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet

Here is how Aurinia Pharmaceuticals (AUPH) and Bausch Health (BHC) have performed compared to their sector so far this year.

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership.

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Will Soghikian - Leerink Partners Ed Arce - H.C. Wainwright David Martin - Bloom Burton Farzin Haque - Jefferies Justin Kim - Oppenheimer Operator Greetings.

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Call Transcript

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.25 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023. Amounts are expressed in U.S. dollars. Total net revenue was $41.5 million for the three months ended June 30, 2023, compared to $28.2 million in the prior year three months ended June 30, 2022, representing growth of approximately 47% year over year. Year to date net revenue increased to $75.9 million for t.

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023.

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the official peer-reviewed journal of the American College of Rheumatology. As part of the AURORA Clinical Program, the AURORA 2 extension study assessed the long-term safety and tolerability of LUPKYNIS® (voclosporin), compared.

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), the beneficial owner of approximately 4.2% of the outstanding common shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today commented on the Company's decision to initiate a review of strategic alternatives, including a potential value-maximizing sale, following MKT Capital's successful withhold campaign at the Company's 2023 Annual General Meeting of Share.

MKT Capital Pleased with Aurinia's Commencement of a Strategic Review Process

Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger.

Aurinia (AUPH) Up on Paving the Way for a Potential Buyout

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?

Thursday, Aurinia's board of directors announced plans to explore strategic alternatives to bolster shareholder value. Investors are piling into the biotech's shares today as a result.

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

Aurinia Pharmaceuticals said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday.

Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout

Shares of Aurinia Pharmaceuticals ( US:AUPH ) are up almost 14% in Friday's premarket activity following a series of director departures and news of a strategic review of potential sale or merger opportunities.

Aurinia Pharmaceuticals Share Surge Shows Investor Support for Board Reboot, Strategic Review

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value.

Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy.

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range was increased to between $135 to $155 million of net product sales. The lupus nephritis treatment market is expected to reach $5.67 billion by 2033.

Aurinia Pharmaceuticals: Still In The Game With Lupkynis Sales

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia's outstanding shares, today condemned the Company's sluggish response to the outcome of its 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023. At the Annual Meeting, Chairman George Milne and Com.

MKT Capital Calls on Aurinia's Board of Directors to Respect the Message Sent by Shareholders at 2023 Annual Meeting

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies, which found that LUPKYNIS® with mycophenolate mofetil (MMF) and low-dose steroids resulted in earlier and greater reductions in proteinuria in lupus nephritis (LN) patients with high proteinuria across biopsy classes, races, and ethnicities. These data w.

LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees.

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Two of Aurinia's largest shareholders wrote tough letters against the AUPH board, leading to two resignations. One of these shareholders also wanted AUPH to sell out.

Aurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not Over

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia's outstanding shares, today commented on the outcome of the Company's 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023. At the Annual Meeting, Chairman George Milne and Compensation Committee Ch.

News for Aurinia Pharmaceuticals Stock (AUPH)